Writing the SBIR Commercialization Plan That Reviewers Actually Believe

The Section That Sinks Otherwise Strong Proposals

The commercialization plan is the most common weakness in SBIR proposals. Study sections, review panels, and program officers across every federal agency report the same pattern: technically excellent proposals paired with commercialization sections that read like afterthoughts. A two-page market overview pasted in the night before submission. A revenue table with no supporting logic. A list of potential customers with no evidence that any of them have been contacted.

This matters because every SBIR agency now evaluates commercial potential as a scored criterion, not a secondary consideration. NIH embeds it in the Significance score. NSF treats it as a standalone review criterion weighted equally with technical merit. DoD uses it to assess transition readiness. DOE requires a dedicated commercialization plan document that will be declined without review if missing.

The 2026 SBIR reauthorization reinforced this direction. The new law increases emphasis on demonstrated commercialization performance, introduces stricter performance benchmarks for repeat awardees, and signals that agencies should fund companies with credible paths to market, not just credible science.

This guide covers what each major agency actually evaluates, how to build each section of the commercialization plan with evidence reviewers trust, and the specific mistakes that cause technically strong proposals to score poorly on commercial potential.

What Each Agency Actually Scores

The commercialization section goes by different names, carries different page limits, and sits within different evaluation frameworks depending on the agency. Treating them as interchangeable is a common and costly mistake.

NIH: Commercial Potential Within Significance

NIH SBIR review follows the same five-criterion structure used for R01 grants: Significance, Investigator(s), Innovation, Approach, and Environment. Commercial potential does not appear as a standalone criterion. Instead, reviewers evaluate it under Significance, where they assess whether the proposed innovation addresses an important unmet need and whether it has a realistic path to reaching patients or end users.

This placement is deceptive. Because commercialization is embedded within Significance, first-time applicants often focus exclusively on the scientific importance of the problem and neglect the market dimensions. Reviewers score Significance on a 1-to-9 scale, and a proposal that demonstrates genuine clinical need but provides no evidence of market viability will not score well. The commercialization plan is uploaded as a separate document (typically 3 pages for Phase I, up to 12 pages for Phase II) and referenced during the Significance discussion.

NIH reviewers want to see that you understand the regulatory pathway, the reimbursement landscape, and the competitive products already on the market. They are often scientists, not businesspeople, so the commercial narrative needs to be specific but accessible. A vague claim about a "$50 billion market" without explaining how your product captures any portion of it will undermine credibility.

NSF: A Standalone, Equally Weighted Criterion

NSF treats commercialization potential as a separate merit review criterion applied alongside intellectual merit and broader impacts. The NSF commercialization plan is a required document with four defined sections: Market Opportunity, Company/Team, Product/Technology and Competition, and Finance and Revenue Model. Each section is evaluated for depth and analytical rigor.

NSF reviewers include both technical experts and individuals with industry or venture experience. They are specifically looking for evidence that the team has talked to potential customers, that the market analysis uses real data rather than generic industry reports, and that the revenue model reflects realistic assumptions about pricing, sales cycles, and customer acquisition. NSF program directors have stated publicly that the quality of the commercialization plan is often the deciding factor between proposals with similar technical scores.

DoD: Transition to the Warfighter

DoD evaluates commercialization under the broader heading of transition potential. The question is not abstract market viability but specific transition: Who in the Department of Defense will use this technology? What acquisition program does it support? What is the pathway from Phase II prototype to Phase III procurement?

DoD Phase I proposals include a commercialization strategy section (typically 2 pages). Phase II proposals require a more detailed commercialization plan plus a Company Commercialization Report (CCR) documenting the outcomes of all prior SBIR awards. For companies with 16 or more Phase II awards in the prior ten fiscal years, the CCR feeds directly into performance benchmark calculations. Companies that fail to meet minimum commercialization benchmarks — averaging at least $100,000 in sales or additional investment per Phase II award, or holding patents equal to 15 percent of Phase II awards — become ineligible to submit new proposals.

The strongest DoD commercialization plans name specific Program Executive Offices, cite Program of Record numbers, and include letters of support from military end users who confirm the operational need.

DOE: A Mandatory Standalone Document

DOE requires a dedicated commercialization plan as a separate PDF upload, limited to 4 pages with 11-point minimum font. If this document is missing at submission, the application is administratively declined without review. There is no recovery.

DOE reviewers evaluate the plan for market understanding, competitive awareness, and the applicant's ability to articulate a realistic path from funded R&D to commercial deployment. For energy technology companies, this means addressing manufacturing scalability, supply chain considerations, and the regulatory or permitting environment relevant to your technology.

Market Analysis That Withstands Scrutiny

The market analysis section is where most commercialization plans lose credibility. The failure mode is almost always the same: an applicant cites a large market number from a secondary source, claims their product addresses some fraction of it, and provides no analytical framework connecting the two.

The TAM-SAM-SOM Framework Done Right

Every SBIR commercialization plan should present market size using the Total Addressable Market (TAM), Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM) framework. But the framework itself is not sufficient. Reviewers evaluate the logic connecting each layer, not just the numbers.

TAM is the total revenue opportunity if every possible customer adopted your solution. For a new rapid diagnostic for sepsis, the TAM might be the total global market for sepsis diagnostics. Source this from published market reports — Gartner, Grand View Research, MarketsandMarkets, IBISWorld, or Statista are all credible. Cite the source, publication year, and compound annual growth rate (CAGR). Data older than 24 months raises questions.

SAM is the portion of TAM that your product can realistically serve given its current form factor, regulatory status, geographic reach, and distribution model. If your diagnostic is a point-of-care device designed for U.S. emergency departments, your SAM is not the global sepsis diagnostics market. It is the U.S. ED-based rapid diagnostics market. This narrowing must be explicit and defensible. Show the filters you applied and cite supporting data for each.

SOM is the revenue you can realistically capture in the next 3 to 5 years given your team size, sales capacity, manufacturing timeline, and competitive position. This is the number reviewers care about most, and it is the one most often fabricated. A credible SOM is built bottom-up: number of target customers multiplied by realistic conversion rate multiplied by annual contract value. If you claim you will capture 5 percent of a $2 billion SAM in year three with a four-person team and no sales force, the reviewer will not believe you.

Top-Down vs. Bottom-Up Convergence

Sophisticated commercialization plans present both approaches and show convergence. The top-down method starts with the published market size and applies filters. The bottom-up method starts with individual customer economics and scales. When both approaches produce estimates within 15 percent of each other, the market sizing becomes credible. When they diverge significantly, it signals that one set of assumptions is wrong.

Sources That Reviewers Trust

Credible market data comes from industry analyst firms (Gartner, IDC, Forrester, Frost & Sullivan), government databases (Census Bureau, Bureau of Labor Statistics, CMS for healthcare), trade association reports, SEC filings of publicly traded competitors, and peer-reviewed market analyses. Your own primary research — customer interviews, pilot data, survey results — is the strongest evidence of all, because it demonstrates direct engagement with the market rather than desk research.

Avoid relying exclusively on a single market research firm, especially for niche markets where their sample sizes may be small. Cross-reference multiple sources. If you cannot find published data for your specific market segment, explain how you derived your estimate from adjacent data and primary research.

Revenue Projections Reviewers Take Seriously

Revenue projections in an SBIR commercialization plan serve a specific purpose: they demonstrate that you have thought rigorously about how your technology generates revenue and on what timeline. Reviewers do not expect precision. They expect internal consistency and realistic assumptions.

The Five-Year Projection Standard

Most agencies expect a five-year revenue projection. The first two years typically overlap with the SBIR-funded project period (Phase I or Phase II). Years three through five project post-SBIR commercial revenue. Experienced reviewers expect the following pattern:

Years 1-2: Negative operating income. Revenue is minimal or zero. Costs are dominated by R&D. This is normal and expected for early-stage technology companies. Do not inflate early-year revenue to make the table look better — it signals inexperience.

Year 3: Initial commercial revenue from early adopters or pilot customers. Revenue should be conservative and tied to specific, named customer segments. If you have letters of intent or pilot agreements, reference them.

Years 4-5: Revenue growth driven by market expansion, additional product lines, or new customer segments. Growth rates should be justifiable. A 300 percent year-over-year increase is not inherently unreasonable for a small-revenue company, but you must explain the mechanism: a distribution partnership, a regulatory clearance that opens new markets, or a manufacturing scale-up that enables lower pricing.

Assumptions Table

Include a separate table or section listing every assumption underlying your projections. Pricing per unit. Units sold per quarter. Customer acquisition cost. Average sales cycle length. Churn rate if applicable. Gross margin. This transparency is what separates a credible projection from a fiction. Reviewers may disagree with your assumptions, but if the assumptions are explicit and reasonable, the projection itself remains useful.

What Kills Revenue Projections

Projections fail when they show hockey-stick growth with no mechanism, when unit economics do not add up (a $10,000 product generating $50 million in revenue from a market of 2,000 potential customers implies 100 percent market capture), or when the projection ignores the sales and marketing investment required to generate the forecasted revenue. If your projection shows $20 million in year-five revenue but your budget includes no sales hires and no marketing spend, the numbers are fiction.

Customer Validation: Letters That Actually Matter

Letters of support are the single most tangible form of commercialization evidence in an SBIR proposal. They transform abstract market claims into demonstrated demand. But their value varies enormously depending on who writes them and what they commit to.

The Hierarchy of Letter Strength

Strongest: Letters of intent with specific commitments. "We intend to purchase 50 units at $X per unit upon successful completion of Phase II and receipt of FDA 510(k) clearance." This letter names a product, a quantity, a price, and a condition. It gives the reviewer concrete evidence of market demand.

Strong: Pilot or beta-test commitments. "We will provide access to our clinical laboratory and 200 patient samples for validation testing during Phase I, and we intend to evaluate the technology for adoption in our 12-hospital network upon successful demonstration." This letter establishes a relationship, provides resources, and signals genuine interest in the technology.

Moderate: Statements of need and interest. "Our organization faces [specific problem]. We currently spend $X per year on [existing solution]. We are interested in evaluating [applicant's technology] as a potential alternative." This letter confirms the problem exists and that a real organization recognizes it, but it does not commit to anything.

Weak: Generic endorsements. "We support this innovative research and believe it has commercial potential." This letter adds almost nothing. Reviewers discount it immediately.

Who Should Write the Letters

Letters from potential paying customers carry the most weight. Letters from channel partners, distributors, or system integrators are strong because they signal market access. Letters from industry experts or consultants carry moderate weight. Letters from collaborators or subcontractors are expected but do not constitute market validation — they are already being paid.

For DoD proposals, a letter from a program manager, TPOC (Technical Point of Contact), or end-user command is exceptionally valuable. For NIH, letters from clinical sites willing to participate in validation studies demonstrate both scientific and commercial viability.

How to Obtain Letters

Start requesting letters 8 to 12 weeks before the submission deadline. Send potential supporters a one-page summary of your project, the specific letter you need, and a draft template they can modify. Make it easy. Most supporters are busy professionals who want to help but will not write a letter from scratch under time pressure. Follow up at the two-week mark. Expect a 50 percent response rate from cold outreach and 80 percent from warm contacts.

Do not fabricate commitments. Reviewers occasionally contact letter writers. If the letter says "we intend to purchase" but the signatory tells a program officer they have never heard of your product, your credibility is destroyed.

Agency-Specific Letter Rules

NSF Phase I no longer accepts letters of support unless specifically required by the program solicitation. NSF does accept letters of collaboration, which describe a specific collaborative activity rather than general support. This distinction matters — submitting a letter of support when only collaboration letters are accepted can result in administrative issues. Always verify the current solicitation requirements.

The Company Commercialization Report and Performance Benchmarks

For companies with prior SBIR awards, the Company Commercialization Report (CCR) is a critical component of Phase II proposals. The CCR documents the commercial outcomes of every prior SBIR award: sales revenue, additional investment, patents, and licensing activity.

How the CCR Affects Your Proposal

Reviewers can see your entire SBIR track record through the CCR. A company that has received ten Phase II awards and generated zero commercial revenue from any of them faces a credibility gap that no amount of market analysis prose can overcome. Conversely, a company that can demonstrate meaningful commercialization from prior awards enters review with built-in credibility.

Performance Benchmarks

SBA requires agencies to enforce minimum commercialization performance benchmarks for repeat SBIR awardees. The thresholds are designed to identify companies that chronically win awards without producing commercial outcomes. A company with 16 or more Phase II awards in the past ten fiscal years must demonstrate either an average of $100,000 in sales and additional investment per Phase II award, or a patent count equal to at least 15 percent of Phase II awards received. Companies that fail both benchmarks are ineligible to submit new Phase I or Direct-to-Phase II proposals.

The Commercialization Achievement Index

DoD calculates a Commercialization Achievement Index (CAI) for companies with four or more Phase II awards from at least two years prior. The CAI is a percentile ranking from 0 to 100 that compares a company's commercialization performance against a randomly selected group of SBIR awardees from comparable time periods. A CAI of 75 means there is a 75 percent probability that the company's commercialization results exceed a random comparison group. While the CAI is not a formal pass/fail gate like performance benchmarks, it provides program managers and reviewers with a normalized measure of a company's commercial track record.

For first-time SBIR applicants, the CCR is essentially empty, which is fine. The absence of prior awards is not held against you. The commercialization plan itself carries the full burden of demonstrating commercial potential.

Competitive Analysis: Honest Assessment Over Salesmanship

The competitive analysis section tests whether you understand the market you propose to enter. Reviewers are subject matter experts. Many of them know your competitors, have reviewed their proposals, or have used their products. Claiming you have no competition, or listing competitors and dismissing them with superficial criticisms, signals naivety.

How to Structure the Analysis

Identify three to five direct competitors and two to three alternative approaches (including the status quo of doing nothing or using manual processes). For each competitor, state what they offer, their market position, their strengths, and their limitations — honestly. Then explain your differentiation: what specific advantage your technology provides and why that advantage matters to the target customer.

Use a comparison table. Columns for key performance parameters (speed, sensitivity, cost, ease of use, scalability) and rows for each competitor plus your technology. Fill in real numbers where possible, estimated ranges where necessary, and "unknown" where data is unavailable. An honest "unknown" is more credible than a fabricated number.

The Differentiation That Matters

Technical superiority alone is rarely sufficient differentiation. Reviewers have seen hundreds of proposals claiming 10x performance improvements. What they want to know is whether that improvement translates into a purchasing decision. A diagnostic that is 10 percent more sensitive but costs five times more and requires specialized training may not displace the incumbent. Your differentiation must connect a technical advantage to a customer value proposition: lower total cost of ownership, faster time to result, reduced workflow complexity, or compliance with a new regulatory requirement.

Building the Full Commercialization Narrative

A commercialization plan is not a collection of independent sections. It is an argument. The market analysis establishes that a real, quantifiable need exists. The competitive analysis shows that current solutions are inadequate. The product description explains how your technology addresses the gap. The revenue model demonstrates a viable business. The customer validation evidence proves that real organizations agree with your analysis. The team section shows that the people executing this plan have the skills and relationships to succeed.

Each section must reinforce the others. If your market analysis identifies hospital laboratory directors as the primary buyer but your letters of support come from academic researchers, the narrative breaks. If your revenue model projects sales into the European market but your regulatory section only discusses FDA clearance, the reviewer notices.

The Team Section

Do not neglect commercial team capabilities. A founding team of three PhD scientists with no business development, sales, or regulatory experience raises a legitimate question: who will actually sell this product? If you plan to hire commercial talent, say so and describe the timeline and profile. If you have an advisory board with relevant commercial experience, feature them. If you have a partnership with an established distributor or OEM, that is among the strongest signals a reviewer can see.

Intellectual Property Strategy

Address your IP position directly. List issued patents and pending applications relevant to the proposed technology. Explain the freedom-to-operate landscape. If there are blocking patents held by competitors, acknowledge them and describe your strategy (design around, license, or challenge). Reviewers respect honesty about IP complexity far more than silence or vague claims of "strong IP position." If your technology is based on trade secrets rather than patents, explain the defensibility of that approach.

The Seven Mistakes That Cost You the Award

Based on patterns observed across thousands of SBIR reviews, these are the commercialization plan failures that consistently drag down otherwise competitive proposals.

1. The afterthought plan. Written in the final 48 hours, it reads like it. Generic market statistics, no customer validation, boilerplate competitive analysis. Reviewers can tell.

2. All TAM, no SOM. Citing a $100 billion global market without narrowing to the addressable and obtainable segments signals that you have not done the analysis. Reviewers want to see the funnel, not just the top of it.

3. Zero customer contact. No letters of support, no interview data, no pilot agreements. The entire commercial case is built from desk research. This is the single most common weakness.

4. Revenue projections disconnected from the narrative. The market analysis describes hospital customers, but the revenue model projects government contract revenue. The pricing section assumes $50,000 per unit, but the competitive analysis shows incumbents at $5,000.

5. Ignoring the regulatory pathway. For life science, medical device, environmental, or energy technologies, the path to market runs through a regulatory agency. A commercialization plan that does not address FDA, EPA, DOE, or relevant state-level regulatory timelines and costs is incomplete.

6. No competitive analysis. Stating "there are no direct competitors" is almost never true and always a red flag. Even if no product exists that does exactly what yours does, there are alternatives that your target customers currently use to address the same problem.

7. Mismatched timeline. Projecting significant commercial revenue in year two when the regulatory pathway alone takes three years. Reviewers with industry experience will catch timeline errors instantly.

Frequently Asked Questions

How long should an SBIR commercialization plan be?

Page limits vary by agency and phase. NIH Phase I allows approximately 3 pages; Phase II allows up to 12 pages. DOE requires a standalone document of no more than 4 pages. NSF includes the commercialization plan as an integrated component of the proposal. DoD Phase I typically allows 2 pages for the commercialization strategy section, with Phase II requiring a more detailed plan plus the Company Commercialization Report. Always check the current solicitation for exact page limits, as they change between solicitation cycles. Regardless of the limit, fill the available space with substantive content. A one-page plan in a three-page allocation tells reviewers you did not take the section seriously.

Can a first-time SBIR applicant write a credible commercialization plan without a sales history?

Yes. First-time applicants are not penalized for lacking prior SBIR commercialization data. Your Company Commercialization Report will be empty, and reviewers understand this. The plan itself must carry the argument. Focus on primary customer research (interviews, surveys, advisory board input), letters of support from potential customers or partners, a clear regulatory and market-entry timeline, and a realistic revenue model built on defensible assumptions. Demonstrating that you have engaged with the market — even without revenue — is what reviewers are evaluating.

Do I need different commercialization plans for Phase I and Phase II?

Fundamentally, yes. A Phase I commercialization plan establishes that you understand the market and have a credible vision for reaching it. A Phase II plan must be significantly more detailed: specific pricing validated by customer feedback, named distribution partners or sales channels, a more granular financial model with cash flow projections, and evidence of commercial traction or partnerships developed during Phase I. Phase II reviewers expect progress. If your Phase II commercialization plan looks identical to your Phase I plan, it suggests that you spent the Phase I period doing only technical work and did not advance your commercial strategy.

How do letters of support differ from letters of collaboration, and which should I include?

Letters of support are statements from third parties endorsing your project or expressing interest in your technology. Letters of collaboration describe a specific activity that the letter writer will perform as part of the project. NSF Phase I currently accepts letters of collaboration but generally does not accept letters of support unless the specific solicitation requires them. NIH accepts both. DoD encourages letters from military end users and potential transition partners. The safest approach is to read the current solicitation language carefully and match the letter format to what is requested. When in doubt, frame letters around specific collaborative activities or concrete expressions of need and purchasing intent, which satisfy requirements at any agency.

What market data sources are credible for SBIR commercialization plans?

Reviewers trust data from established industry analyst firms (Gartner, IDC, Forrester, Frost & Sullivan, Grand View Research), government statistical databases (Census Bureau, Bureau of Labor Statistics, CMS, NIH RePORTER), trade association reports, and SEC filings of publicly traded competitors. Your own primary research — customer discovery interviews, pilot program data, survey results from target users — is the strongest evidence because it demonstrates direct market engagement. Avoid citing only a single source, especially for niche markets. Cross-reference multiple data points, cite publication dates, and note compound annual growth rates where available. Data older than 24 months should be supplemented with more recent primary research or alternative sources.

Granted helps small businesses find and apply for SBIR opportunities across all federal agencies with AI-powered grant discovery and proposal development tools.